Safety of Bisphosphonates in the Treatment of Osteoporosis

Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Original languageEnglish
JournalAmerican Journal of Medicine
Volume122
Issue number2 SUPPL.
DOIs
StatePublished - 2009

Fingerprint

Diphosphonates
Osteoporosis
Safety
Musculoskeletal Pain
Fracture Healing
Hypocalcemia
Therapeutics
Chronic Pain
Atrial Fibrillation
Kidney

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Safety of Bisphosphonates in the Treatment of Osteoporosis. / Recker, Robert R.; Lewiecki, E. Michael; Miller, Paul D.; Reiffel, James.

In: American Journal of Medicine, Vol. 122, No. 2 SUPPL., 2009.

Research output: Contribution to journalArticle

Recker, Robert R. ; Lewiecki, E. Michael ; Miller, Paul D. ; Reiffel, James. / Safety of Bisphosphonates in the Treatment of Osteoporosis. In: American Journal of Medicine. 2009 ; Vol. 122, No. 2 SUPPL.
@article{90b7b9e4a0a44d47bd5f8061df4efc68,
title = "Safety of Bisphosphonates in the Treatment of Osteoporosis",
abstract = "In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).",
author = "Recker, {Robert R.} and Lewiecki, {E. Michael} and Miller, {Paul D.} and James Reiffel",
year = "2009",
doi = "10.1016/j.amjmed.2008.12.004",
language = "English",
volume = "122",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Safety of Bisphosphonates in the Treatment of Osteoporosis

AU - Recker, Robert R.

AU - Lewiecki, E. Michael

AU - Miller, Paul D.

AU - Reiffel, James

PY - 2009

Y1 - 2009

N2 - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

AB - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

UR - http://www.scopus.com/inward/record.url?scp=58949086108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949086108&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.12.004

DO - 10.1016/j.amjmed.2008.12.004

M3 - Article

VL - 122

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 SUPPL.

ER -